Arcutis Biotherapeutics Inc ARQT

NAS: ARQT | ISIN: US03969K1088 14/11/2024

9,930 USD (-5,16%)

(-5,16%) 14/11/2024

Toon enkel gratis nieuws

1 december 2022 · MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis · Persbericht

8 september 2022 · LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million · Persbericht

30 augustus 2022 · New Campaign From Arcutis Aims To Expose The Impact Of Psoriasis On Physical, Mental, And Emotional Wellbeing · Persbericht

18 maart 2021 · Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo · Persbericht

17 maart 2021 · Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021 · Persbericht

25 februari 2021 · Arcutis to Present at the Cowen 41st Annual Health Care Conference · Persbericht

3 februari 2021 · Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock · Persbericht

1 februari 2021 · Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock · Persbericht

1 februari 2021 · Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis · Persbericht

20 januari 2021 · Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe